Could be but the financing, as distasteful as it is, shields that to a degree. I'll admit these people have been unsuccessful and have tried to survive by what appear to be scurrilous means but you can't say that isn't the way of most biotechs who don't hit early. You're chasing a scientific home run in most cases and some never hit it. These (DCTH) people may be disorganized, unlucky, bad people and then again they may also have something worth buying by a larger player in the oncology field. Those two factors aren't necessarily mutually exclusive. You can be a complete douche and still have something of value. But I would agree that they are in bad shape unless the news gets a lot better in a hurry in terms of someone making an overt move or there are more specific and significant scientific breakthroughs. If the science is valuable enough they won't have to pursue a partner. Pursuing a partner when it's such a small industry often means you don't have anything real. They'll find you. The results are published. JMO
News 
Market Data 
Discover 
